Enhanced expression of early mitotic inhibitor‑1 predicts a poor prognosis in esophageal squamous cell carcinoma patients

Guan,Chengqi; Zhang,Jianfeng; Zhang,Jianguo; Shi,Hui; Ni,Runzhou

doi:10.3892/ol.2016.4611

Enhanced expression of early mitotic inhibitor‑1 predicts a poor prognosis in esophageal squamous cell carcinoma patients

Authors:
- Chengqi Guan
- Jianfeng Zhang
- Jianguo Zhang
- Hui Shi
- Runzhou Ni
View Affiliations

Affiliations: Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: May 18, 2016 https://doi.org/10.3892/ol.2016.4611
Pages: 114-120
Copyright: © Guan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Early mitotic inhibitor-1 (Emi1), as a key cell cycle regulatory gene, induces S phase and mitotic entry by controlling anaphase‑promoting complex substrates. Emi1 overexpression may be a prognostic factor for patients with invasive breast cancer. However, its expression and clinical significance in esophageal squamous cell carcinoma (ESCC) remain unknown. In the present study, Emi1 was overexpressed in ESCC samples, contrarily to their neighboring normal tissues. The expression of Emi1 was correlated with histological differentiation (P=0.032), lymphatic metastasis (P=0.006) and Ki‑67 expression (P=0.028). Multivariate analysis indicated that the presence of lymphatic metastasis and the protein expression levels of Emi1 and Ki‑67 were all independent prognostic factors for ESCC patients (P=0.042, 0.018 and 0.001, respectively). In vitro, however, the expression of Emi1 was upregulated in the ECA109 cell line following release from serum starvation. In addition, depletion of endogenous Emi1 by small interfering RNA could effectively reduce cell proliferation. Thus, the present data indicated that Emi1 expression was upregulated in ESCC tissues and correlated with poor survival in ESCC patients, and suggested that Emi1 may be an independent prognostic factor for ESCC patients.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Pourhoseingholi MA, Vahedi M and Baghestani AR: Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench. 8:19–27. 2015.PubMed/NCBI
3	Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in China, 2003–2005: A population-based study. Int J Cancer. 136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
4	Lagergren J and Lagergren P: Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 63:232–248. 2013. View Article : Google Scholar : PubMed/NCBI
5	Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 39:295–312. 1999. View Article : Google Scholar : PubMed/NCBI
6	Wolgemuth DJ and Roberts SS: Regulating mitosis and meiosis in the male germ line: Critical functions for cyclins. Philos Trans R Soc Lond B Biol Sci. 365:1653–1662. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kronja I and Orr-Weaver TL: Translational regulation of the cell cycle: When, where, how and why? Philos Trans R Soc Lond B Biol Sci. 366:3638–3652. 2011. View Article : Google Scholar : PubMed/NCBI
8	Wang Y, Fei M, Cheng C, Zhang D, Lu J, He S, Zhao Y, Wang Y and Shen A: Jun activation domain-binding protein 1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas. Cancer Biol Ther. 7:460–467. 2008. View Article : Google Scholar : PubMed/NCBI
9	Song Y, Zhao C, Dong L, Fu M, Xue L, Huang Z, Tong T, Zhou Z, Chen A, Yang Z, et al: Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis. Carcinogenesis. 29:307–315. 2008. View Article : Google Scholar : PubMed/NCBI
10	Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S and Müller W: Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer. 94:2874–2881. 2002. View Article : Google Scholar : PubMed/NCBI
11	Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H and Sugimachi K: Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res. 8:817–822. 2002.PubMed/NCBI
12	Chetty R and Simelane S: p53 and cyclin A protein expression in squamous carcinoma of the oesophagus. Pathol Oncol Res. 5:193–196. 1999. View Article : Google Scholar : PubMed/NCBI
13	Bernis C, Vigneron S, Burgess A, Labbé JC, Fesquet D, Castro A and Lorca T: Pin1 stabilizes Emi1 during G2 phase by preventing its association with SCF(betatrcp). EMBO Rep. 8:91–98. 2007. View Article : Google Scholar : PubMed/NCBI
14	Miller JJ, Summers MK, Hansen DV, Nachury MV, Lehman NL, Loktev A and Jackson PK: Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev. 20:2410–2420. 2006. View Article : Google Scholar : PubMed/NCBI
15	Moshe Y, Bar-On O, Ganoth D and Hershko A: Regulation of the action of early mitotic inhibitor 1 on the anaphase-promoting complex/cyclosome by cyclin-dependent kinases. J Biol Chem. 286:16647–16657. 2011. View Article : Google Scholar : PubMed/NCBI
16	Reimann JD, Gardner BE, Margottin-Goguet F and Jackson PK: Emi1 regulates the anaphase-promoting complex by a different mechanism than Mad2 proteins. Genes Dev. 15:3278–3285. 2001. View Article : Google Scholar : PubMed/NCBI
17	Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM and Jackson PK: Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell. 105:645–655. 2001. View Article : Google Scholar : PubMed/NCBI
18	Hsu JY, Reimann JD, Sørensen CS, Lukas J and Jackson PK: E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC (Cdh1). Nat Cell Biol. 4:358–366. 2002. View Article : Google Scholar : PubMed/NCBI
19	Margottin-Goguet F, Hsu JY, Loktev A, Hsieh HM, Reimann JD and Jackson PK: Prophase destruction of Emi1 by the SCF (betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell. 4:813–826. 2003. View Article : Google Scholar : PubMed/NCBI
20	Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu C, Shen A, Wang Y, Li C, Yuan Q, et al: Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: Correlation with Skp2 stability and degradation of p27(Kip1). Hum Pathol. 44:365–373. 2013. View Article : Google Scholar : PubMed/NCBI
21	Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H and Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 6:4064–4068. 2000.PubMed/NCBI
22	Roth JA and Cristiano RJ: Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst. 89:21–39. 1997. View Article : Google Scholar : PubMed/NCBI
23	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
24	Roncalli M, Bosari S, Marchetti A, Buttitta F, Bossi P, Graziani D, Peracchia A, Bonavina L, Viale G and Coggi G: Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. Lab Invest. 78:1049–1057. 1998.PubMed/NCBI
25	Gütgemann I, Lehman NL, Jackson PK and Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol. 21:445–454. 2008. View Article : Google Scholar : PubMed/NCBI
26	Liu X, Wang H, Ma J, Xu J, Sheng C, Yang S, Sun L and Ni Q: The expression and prognosis of Emi1 and Skp2 in breast carcinoma: Associated with PI3K/Akt pathway and cell proliferation. Med Oncol. 30:7352013. View Article : Google Scholar : PubMed/NCBI
27	Sheri A and Dowsett M: Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Ann Oncol. 23(Suppl 10): x219–x227. 2012. View Article : Google Scholar : PubMed/NCBI
28	He WL, Li YH, Yang DJ, Song W, Chen XL, Liu FK, Wang Z, Li W, Chen W, Chen CY, et al: Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur J Surg Oncol. 39:141–149. 2013. View Article : Google Scholar : PubMed/NCBI
29	Harbour JW and Dean DC: The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev. 14:2393–2409. 2000. View Article : Google Scholar : PubMed/NCBI